IPP Bureau

India's clinical research ambitions need more than regulatory reforms: Experts
India's clinical research ambitions need more than regulatory reforms: Experts

By IPP Bureau - June 29, 2026

At the latest Indian Pharma Post E-Conference, leading experts highlighted the need for accredited trial sites, skilled investigators, digital ecosystems, and greater public trust

Health Ministry proposes faster licensing timelines for medical device manufacturers
Health Ministry proposes faster licensing timelines for medical device manufacturers

By IPP Bureau - June 29, 2026

The proposed changes seek to shorten the statutory timelines for granting manufacturing licences across various risk categories

India to launch revamped Anemia Mukt Bharat Abhiyaan with expanded 7x7x7 strategy
India to launch revamped Anemia Mukt Bharat Abhiyaan with expanded 7x7x7 strategy

By IPP Bureau - June 29, 2026

The transition of the existing Anemia Mukt Bharat programme into Anemia Mukt Bharat Abhiyaan signals a shift towards a more comprehensive, technology-enabled and community-driven approach

Diabetes driving surge in early cataracts among Indians in 40s & 50s
Diabetes driving surge in early cataracts among Indians in 40s & 50s

By IPP Bureau - June 29, 2026

India is home to more than 101 million adults living with diabetes and another 136 million with prediabetes

Strides Pharma divests majority stake in Pivot Path for Rs. 100 Cr
Strides Pharma divests majority stake in Pivot Path for Rs. 100 Cr

By IPP Bureau - June 29, 2026

The deal marks Strides' latest move to monetise high-growth businesses while retaining exposure to their future upside

Johnson & Johnson launches first-in-human SKYWARD trial for carotid IVL system
Johnson & Johnson launches first-in-human SKYWARD trial for carotid IVL system

By IPP Bureau - June 29, 2026

Carotid artery disease accounts for up to 30% of all strokes

Efzimfotase alfa shows strong Phase III results in pediatric hypophosphatasia trial
Efzimfotase alfa shows strong Phase III results in pediatric hypophosphatasia trial

By IPP Bureau - June 29, 2026

The study also met its key secondary endpoint for bone health

Sanofi Foundation doubles down on children and youth with €15 milliion annual push
Sanofi Foundation doubles down on children and youth with €15 milliion annual push

By IPP Bureau - June 29, 2026

The Foundation says it is working alongside NGOs, healthcare professionals, patient groups, and local communities to build programs

PeptiStar tests Asahi Kasei’s heat-free system to speed up API manufacturing
PeptiStar tests Asahi Kasei’s heat-free system to speed up API manufacturing

By IPP Bureau - June 29, 2026

Otsuka reports strong Phase 3b results for centanafadine XR in adults with ADHD
Otsuka reports strong Phase 3b results for centanafadine XR in adults with ADHD

By IPP Bureau - June 29, 2026

The investigational treatment is showing statistically significant improvements in ADHD symptoms versus placebo at week 8

Roche launches AXELIOS 1 sequencing platform powered by SBX technology
Roche launches AXELIOS 1 sequencing platform powered by SBX technology

By IPP Bureau - June 29, 2026

Targeting major leap in genomics speed, scale and cost efficiency

Merck names Miguel Alcalde to lead global commercial strategy;  Monia Vial to head North America
Merck names Miguel Alcalde to lead global commercial strategy; Monia Vial to head North America

By IPP Bureau - June 26, 2026

The appointments come as Andrew Paterson, who has spent 31 years with the company, prepares to retire

Merck wins EU nod for KEYTRUDA-Padcev regimen in muscle-invasive bladder cancer
Merck wins EU nod for KEYTRUDA-Padcev regimen in muscle-invasive bladder cancer

By IPP Bureau - June 26, 2026

The approval is based on results from the pivotal Phase 3 KEYNOTE-905 trial

Reliance-backed Karkinos Healthcare crosses 1 lakh cervical cancer screening in India
Reliance-backed Karkinos Healthcare crosses 1 lakh cervical cancer screening in India

By IPP Bureau - June 26, 2026

Karkinos’ model aims to close both gaps by combining World Health Organization-recommended HPV DNA testing with a digitally enabled continuum of care

Eli Lilly seals Centessa acquisition as it bets big on next-gen sleep disorder drugs
Eli Lilly seals Centessa acquisition as it bets big on next-gen sleep disorder drugs

By IPP Bureau - June 26, 2026

Centessa is a clinical-stage biotech focused on developing orexin receptor 2 agonists

Latest Stories

Interviews

Packaging